Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Hypocomplementemic Urticarial Vasculitis Syndrome

How Accurate Are C1q and Anti-C1q Tests for HUVS? Explained

At a Glance

Low C1q and anti-C1q antibodies can provide clues in HUVS, but neither test has a universal sensitivity or specificity and neither confirms nor rules out the disease alone. Doctors combine repeated complement results with symptoms, skin biopsy findings, and organ evaluation.

If you are wondering about the exact accuracy—the sensitivity and specificity—of low C1q and anti-C1q antibody tests for Hypocomplementemic Urticarial Vasculitis Syndrome (HUVS), the short answer is that no universally reliable percentages exist [1][2].

What are these tests?

  • Complement is a group of immune system proteins (including one called C1q) that help fight disease.
  • Anti-C1q antibodies are immune proteins that mistakenly target and attack your own C1q.

HUVS is a very rare autoimmune condition involving inflamed blood vessels and low complement levels. Because it is so rare, medical studies are small and use different definitions, making it impossible to calculate precise accuracy rates [3][4].

What research does tell us is that these tests are helpful clues but are not definitive on their own. They can be normal in people who truly have HUVS, and they can be abnormal in people who actually have other conditions like Systemic Lupus Erythematosus (SLE) [5][6]. Navigating diagnostic uncertainty with a rare disease is highly stressful, but remember that a normal or non-specific test result does not invalidate your real symptoms.

Test Sensitivity: Can a Normal Result Rule Out HUVS?

Sensitivity measures how well a test identifies people who actually have a disease. In HUVS, neither a C1q level nor an anti-C1q antibody test catches every case [5].

  • Low C1q Levels: Medical literature suggests that a low C1q blood level is generally the more sensitive marker, meaning it is more consistently found in patients with the condition than the antibodies are [5].
  • Anti-C1q Antibodies: Having these autoantibodies is a classic feature of HUVS, but they are not found in everyone. In one medical review, they were detected in only about half of patients with HUV (the skin-focused form of the disease) [5]. Even in a small, specialized study looking at 12 patients with kidney involvement, only 67% (8 out of 12) had positive anti-C1q antibodies [3].

The Bottom Line: A normal anti-C1q antibody test does not rule out HUVS. You can still have the condition even if this specific test comes back negative [5][3].

Test Specificity: Are These Tests Exclusive to HUVS?

Specificity measures how well a test correctly identifies people who do not have the disease (the true-negative rate). Neither of these tests is exclusive to HUVS, meaning an abnormal result is not specific to this one disease [6][7].

  • Systemic Lupus Erythematosus (SLE): This is the most common reason for an abnormal test when looking for HUVS. Both genuinely low C1q levels and the presence of anti-C1q antibodies are frequently seen in patients with active lupus [6][7].
  • Other Autoimmune Diseases: Anti-C1q antibodies can also be found in people with other types of vasculitis (such as rheumatoid arthritis-associated vasculitis) and other systemic autoimmune conditions [6].

Because these lab results overlap so heavily with other conditions, a positive test cannot confirm HUVS without other supporting evidence [6][7].

The Challenge of Unstandardized Lab Tests

Another reason we lack exact accuracy numbers is that different laboratories use different methods and equipment to run these tests.

Research shows that different commercial test kits (like ELISA assays, a common type of lab test used to detect antibodies) for anti-C1q antibodies only have “moderate agreement” with one another [8]. This means a blood sample might test positive at one lab but negative at another [8]. Additionally, how the C1q protein is handled and measured in the lab can change the results, making it impossible to establish a single, universal cutoff point for diagnosing HUVS [9].

Why the Full Picture Matters

Because blood tests alone cannot make or break a diagnosis, doctors must look at the whole picture. A diagnosis of HUVS relies on interpreting repeatedly low complement levels alongside:

  • Clinical Findings: Having recurrent urticarial lesions (hives) where an individual spot lasts longer than 24 hours, leaves a bruise or dark mark, or causes a burning sensation rather than just itching [10].
  • Skin Biopsy: Examining a fresh skin lesion under a microscope to check for leukocytoclastic vasculitis (inflammation, damage to small blood vessels, and leakage of red blood cells or proteins like fibrin). A biopsy supports the diagnosis of urticarial vasculitis but cannot confirm HUVS on its own [10][11].
  • Organ Evaluation: HUVS can involve systemic inflammation, though not everyone develops all of these problems. Your doctor will likely evaluate your kidneys (using a urinalysis, urine protein test, kidney function/eGFR blood test, and blood pressure check), lungs (if you have breathing issues), and eyes [3][4]. Seek urgent medical care if you experience new breathing difficulty, coughing up blood, blood in your urine, significantly reduced urination, or sudden vision changes.

Summary: What Your Results Mean

Test Result What it might mean What it CANNOT do
Low C1q Level Often seen in HUVS, but also seen in lupus and other autoimmune diseases. Cannot diagnose HUVS on its own.
Positive Anti-C1q Antibodies Supports a HUVS diagnosis, but also commonly seen in active lupus nephritis and other types of vasculitis. Cannot confirm HUVS without matching symptoms and biopsy results.
Normal Results You may still have HUVS, as these markers are absent in many confirmed cases. Cannot completely rule out HUVS if clinical symptoms strongly suggest it.

Common questions in this guide

Can a normal anti-C1q result rule out HUVS?
No. Anti-C1q antibodies are absent in some people with HUVS, so a negative result does not exclude the condition. Doctors interpret the result with repeated complement levels, symptoms, a skin biopsy when appropriate, and evaluation for organ involvement.
Is low C1q more sensitive than anti-C1q antibodies in HUVS?
Usually, low C1q is considered the more sensitive marker, meaning it is found more consistently in HUVS. However, neither test catches every case. In published reports, anti-C1q antibodies were found in about half of patients with the skin-focused form and in 8 of 12 patients in one small kidney-involvement study.
Does a low C1q level confirm HUVS?
No. Low C1q can occur in HUVS, but it is also common in active lupus and can appear with other autoimmune diseases. It is a supporting clue, not a stand-alone diagnosis.
Why do C1q test accuracy estimates vary between laboratories?
Different laboratories may use different test kits, methods, and cutoffs, especially for anti-C1q antibody testing. Commercial antibody tests may only agree moderately, so the same sample can produce different results at different laboratories. This makes universal sensitivity and specificity estimates difficult.
Can low C1q or anti-C1q antibodies occur in lupus?
Yes. Both low C1q and anti-C1q antibodies can occur in active systemic lupus erythematosus, and anti-C1q antibodies may also appear in other types of vasculitis and autoimmune conditions. A positive result therefore does not distinguish HUVS from lupus without the clinical context and other testing.
What other findings help doctors evaluate possible HUVS?
Doctors look for repeatedly low complement levels, hives that last longer than 24 hours or leave bruising, and a skin biopsy from a fresh lesion showing small-vessel inflammation. They may also check the kidneys, lungs, and eyes for organ involvement. These findings are interpreted together because no single C1q result confirms HUVS.

Get notified when new evidence is published on Hypocomplementemic urticarial vasculitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Clinical Profile of Patients with Urticarial Vasculitis in China: A Retrospective of 142 Cases.

    Hu W, Zhu Y, Geng S, et al.

    Journal of inflammation research 2026; (19()):576374 doi:10.2147/JIR.S576374.

    PMID: 41877830
  2. 2

    Childhood-onset hypocomplementaemic urticarial vasculitis in France: phenotypic and genotypic diversity in 10 children.

    Bianchi C, Melki I, Sisirak V, et al.

    Pediatric rheumatology online journal 2026; (24(1)).

    PMID: 41807955
  3. 3

    Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis.

    Corthier A, Jachiet M, Bertin D, et al.

    BMC nephrology 2022; (23(1)):67 doi:10.1186/s12882-022-02689-8.

    PMID: 35172758
  4. 4

    Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis).

    Sjöwall C, Mandl T, Skattum L, et al.

    Rheumatology (Oxford, England) 2018; (57(8)):1400-1407 doi:10.1093/rheumatology/key110.

    PMID: 29718374
  5. 5

    [Hypocomplementemic urticarial vasculitis].

    Jachiet M, Flageul B, Bouaziz JD, et al.

    La Revue de medecine interne 2018; (39(2)):90-98 doi:10.1016/j.revmed.2017.03.005.

    PMID: 28457680
  6. 6

    Clinical utility of anti-C1q antibody in primary and secondary vasculitic conditions.

    Jayakanthan K, Gupta AN, Mathew J, et al.

    International journal of health sciences 2017; (11(5)):3-6.

    PMID: 29114186
  7. 7

    Clinical and Serological Correlates of Serum C1Q and Anti-C1Q Antibodies in South Africans With Systemic Lupus Erythematosus.

    Tikly M, Skattum L, Makda MA

    Journal of clinical laboratory analysis 2025; (39(18)):e70087 doi:10.1002/jcla.70087.

    PMID: 40719289
  8. 8

    Clinical utility and performance of anti-C1q antibodies for SLE: comparative analysis of three different assays.

    Gonzalez-Treviño M, Hetrick MD, Sanchez-Rodriguez A, et al.

    Lupus science & medicine 2026; (13(1)) doi:10.1136/lupus-2025-001896.

    PMID: 41791798
  9. 9

    Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation.

    Dijkstra DJ, van de Bovenkamp FS, Abendstein L, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2023; (120(50)):e2310666120 doi:10.1073/pnas.2310666120.

    PMID: 38048459
  10. 10

    Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey.

    Krause K, Bonnekoh H, Jelden-Thurm J, et al.

    Clinical and translational allergy 2023; (13(10)):e12305 doi:10.1002/clt2.12305.

    PMID: 37876033
  11. 11

    A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria.

    Puhl V, Bonnekoh H, Scheffel J, et al.

    Clinical and translational allergy 2021; (11(2)):e12031 doi:10.1002/clt2.12031.

    PMID: 33949135

This page explains the limits of C1q and anti-C1q testing for HUVS for educational purposes only. It does not replace medical advice; ask your healthcare professional to interpret your results alongside your symptoms and other tests.